key: cord-1053828-m7j0t6hz
authors: Lv, Zhe; Deng, Yong-Qiang; Ye, Qing; Cao, Lei; Sun, Chun-Yun; Fan, Changfa; Huang, Weijin; Sun, Shihui; Sun, Yao; Zhu, Ling; Chen, Qi; Wang, Nan; Nie, Jianhui; Cui, Zhen; Zhu, Dandan; Shaw, Neil; Li, Xiao-Feng; Li, Qianqian; Xie, Liangzhi; Wang, Youchun; Rao, Zihe; Qin, Cheng-Feng; Wang, Xiangxi
title: Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
date: 2020-06-10
journal: bioRxiv
DOI: 10.1101/2020.06.02.129098
sha: 354aad5f45ce5e17a6367ab0287bffc043404273
doc_id: 1053828
cord_uid: m7j0t6hz

The COVID-19 pandemic caused by the SARS-CoV-2 virus has resulted in an unprecedented public health crisis. There are no approved vaccines or therapeutics for treating COVID-19. Here we reported a humanized monoclonal antibody, H014, efficiently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 at nM level by engaging the S receptor binding domain (RBD). Importantly, H014 administration reduced SARS-CoV-2 titers in the infected lungs and prevented pulmonary pathology in hACE2 mouse model. Cryo-EM characterization of the SARS-CoV-2 S trimer in complex with the H014 Fab fragment unveiled a novel conformational epitope, which is only accessible when the RBD is in open conformation. Biochemical, cellular, virological and structural studies demonstrated that H014 prevents attachment of SARS-CoV-2 to its host cell receptors. Epitope analysis of available neutralizing antibodies against SARS-CoV and SARS-CoV-2 uncover broad cross-protective epitopes. Our results highlight a key role for antibody-based therapeutic interventions in the treatment of COVID-19. One sentence summary A potent neutralizing antibody conferred protection against SARS-CoV-2 in an hACE2 humanized mouse model by sterically blocking the interaction of the virus with its receptor.

against SARS-CoV-2 (7-9). Among these, CR3022, a weakly neutralizing antibody 78 against SARS-CoV, is tight binding, but non-neutralizing for SARS-CoV-2, 79 indicative of possible conformational differences in the neutralizing epitopes (9). 80 More recent studies have reported two SARS-CoV neutralizing antibodies, 47D11 81 and S309, that have been shown to neutralize SARS-CoV-2 as well (10, 11), 82 suggesting that broad cross-neutralizing epitopes exist within lineage B. Convalescent 83 plasma containing SARS-CoV-2 neutralizing antibodies (NAbs) have been shown to 84 confer clear protection in 13) without any Fab bound was also observed during 3D classification of the cryo-EM 144 data, albeit in the presence of excessive Fab, suggesting that the binding sites of H014 145 are exposed through protein "breathing" followed by a stochastic RBD movement 146 ( Fig. 2A) . We determined asymmetric cryo-EM reconstructions of the 4 states at 3.4 -147 3.6 Å (figs. S3-S6 and table S1). However, the electron potential maps for binding 148 interface between RBD and H014 are relatively weak due to conformational 149 heterogeneity. To solve this problem, focusing classification and refinement by using 196 Moreover, ACE2 could be displaced from trimeric S and replaced by H014 (Fig. 3C ).

To further verify these results in a cell-based viral infection model, real time analysis was carried out to quantify the amount of virus remaining on the host cell 199 surface, which were exposed to antibodies pre-or post-virus attachment to cells at (2, 9, 20) . In contrast to the hinge-like movement of the RBD observed in most 217 structures, the conformational transition from "close" to "open" observed in our 218 structures mainly involves two steps of rotations: 1) counterclockwise movement of 219 SD1 by~25°encircling the hinge point (at residue 320); 2) the RBD rotates itself 220 counterclockwise by~60° (Fig. 4B) . These conformational rotations of the SD1 and 221 RBD at proximal points relay an amplified alteration at the distal end, leading to 222 opening up of adequate space for the binding of H014 or ACE2 (Fig. 4B ). 

Methods enzymol 579, 125-157 (2016) 

A pneumonia outbreak associated with a new coronavirus of 278 probable bat origin

Structure, Function, and Antigenicity of the SARS-CoV

Rapid development of an 284 inactivated vaccine for SARS-CoV-2

Establishment and validation of a pseudovirus neutralization assay for 316 SARS-CoV-2

A mouse model of SARS-CoV-2 infection and 320 pathogenesis

Cryo-EM structure of the 2019-nCoV spike in the prefusion 322 conformation

Values are mean ± SD. Experiments were performed in 588 triplicate. (C) BIAcore SPR kinetics of competitive binding of H014

For both panels, SARS-CoV-2 S trimer was loaded onto the 590 sensor. In the upper panel, H014 was first injected, followed by ACE2, whereas in 591 the lower panel, ACE2 was injected first and then H014. The control groups are 592 depicted by black curves. (D) Amount of virus on the cell surface

High concentrations of H014 596 prevent attachment of SARS-CoV-2 to the cell surface when SARS-CoV-2 was 597 exposed to H014 before cell attachment. Values represent mean ± SD. Experiments 598 were performed in duplicates. (E) Clashes between H014 Fab and ACE2 upon 599 binding to SARS-CoV-2 S

Inset is a zoomed-in view of the 601 interactions of the RBD, H014 and ACE2 and the clashed region (oval ellipse) 602 between H014 and ACE2. The H014 Fab light and heavy chains, ACE2, and RBD 603 are presented as cartoons. The epitope, RBM and the overlapped binding region of 604 ACE2 and H014 on RBD are highlighted in green

Breathing of the S1 subunit and epitopes of neutralizing antibodies 629 (A) H014 can only interact with the "open" RBD, whereas the "closed" RBD is 630 inaccessible to H014. The "open" RBD and RBD bound H014 are depicted in 631 lighter colors corresponding to the protein chain they belong to. Color scheme is 632 the same as in Fig

SARS-CoV-2 transition from the closed state to the open state. SD1: subdomain 1, 634 SD2: subdomain 2, RBD': RBD (closed state) from adjacent monomer

The red dot indicates the hinge point. The angles between the RBD 637 and SD1 are labeled. (C) Epitope location analysis of neutralizing antibodies on 638 SARS-CoV and SARS-CoV-2 S trimers. The S trimer structures with one RBD 639 open and two RBD closed from SARS-CoV and SARS-CoV-2 were used to show 640 individual epitope information, which is highlighted in green. The accessible and 641 in-accessible states are encircled and marked by green ticks and red crosses

RBDs are rendered as molecular surfaces in light blue. Footprints of 644 different mAbs are highlighted in different colors as labeled in the graph. Note: 645 epitopes recognized by indicated antibodies are labeled in blue